Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCELERATE3: BMAC for Knee Osteoarthritis
NCT06216028Phase 3Not yet recruiting
- Sponsor
- CELL Technologies Inc.
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of autologous bone marrow cell concentrate in osteoarthritis (OA), sponsored by CELL Technologies Inc.. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
autologous bone marrow cell concentrate
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06216028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06216028.